NCT02115165View on ClinicalTrials.gov

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

PHASE2UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2020

Conditions
Non-seminomatous Germ-cell Tumors
Interventions
DRUG

Cabazitaxel

On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour

Trial Locations (1)

94805

RECRUITING

Gustave Roussy Cancer Campus Grand Paris, Villejuif

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER